Roche Diagnostics Offers Complete Infectious Disease Serology Solution
21 Aug 2008Roche Diagnostics today announced the availability in the UK and Ireland of its new cobas® Anti-HCV assay, extending the already comprehensive range of cobas® infectious disease immunoassays.
cobas® Anti-HCV is one of the most rapid and sensitive screening assays available for the detection of antibodies to hepatitis C virus (HCV) [1], allowing infection to be diagnosed in the very early stages. In addition, cobas® Anti-HCV is accurate and reliable in the detection of different HCV genotypes, demonstrating 100% sensitivity in the detection of highly divergent strains in confirmed anti-HCV positive samples [1] and a clinical specificity of 99.71% [1].
“cobas® Anti-HCV is the latest assay to form part of our complete infectious disease serology solution for laboratory users, and demonstrates Roche’s commitment to addressing customer needs in terms of laboratory efficiency and convenience”, commented Malcolm Sheppard, Serology Development Manager.
The Roche complete serology solution for infectious diseases includes: cobas® HBsAg II for the enhanced recognition of hepatitis B Virus (HBV) variants and mutants; and cobas® HIV combi, the world’s first automated HIV immunoassay for the combined detection of HIV antigen and antibodies, allowing early detection of HIV infection and reliable recognition of HIV variants.
In addition to the comprehensive selection of assays for hepatitis and HIV, the complete Roche serology solution also includes a wide range of TORCH assays (Toxo IgG and Toxo IgM used in the detection of Toxoplasma gondii; Rubella IgG and Rubella IgM) and Syphilis assays (TPLA IgG and IgM; RPR).
Roche serology assays are rapid, reliable and easy to use, offering flexibility for use on all Roche immunodiagnostic testing platforms and allowing laboratories of any size to offer a complete infectious disease diagnostic service.
References:
1. Data on file at Roche. Details on request.